West Coast Financial LLC Sells 4,008 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

West Coast Financial LLC reduced its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 5.6% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 68,127 shares of the biopharmaceutical company’s stock after selling 4,008 shares during the quarter. West Coast Financial LLC’s holdings in Halozyme Therapeutics were worth $3,257,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in HALO. Verdence Capital Advisors LLC lifted its position in Halozyme Therapeutics by 1.9% during the third quarter. Verdence Capital Advisors LLC now owns 13,232 shares of the biopharmaceutical company’s stock worth $757,000 after acquiring an additional 252 shares during the last quarter. GAMMA Investing LLC boosted its stake in Halozyme Therapeutics by 67.7% in the 3rd quarter. GAMMA Investing LLC now owns 867 shares of the biopharmaceutical company’s stock valued at $50,000 after purchasing an additional 350 shares during the period. Juncture Wealth Strategies LLC grew its holdings in Halozyme Therapeutics by 3.6% in the 3rd quarter. Juncture Wealth Strategies LLC now owns 12,058 shares of the biopharmaceutical company’s stock valued at $690,000 after buying an additional 415 shares in the last quarter. Diversify Advisory Services LLC increased its position in Halozyme Therapeutics by 8.5% during the 3rd quarter. Diversify Advisory Services LLC now owns 5,331 shares of the biopharmaceutical company’s stock worth $305,000 after buying an additional 418 shares during the period. Finally, Sheaff Brock Investment Advisors LLC lifted its holdings in shares of Halozyme Therapeutics by 7.7% during the third quarter. Sheaff Brock Investment Advisors LLC now owns 7,118 shares of the biopharmaceutical company’s stock worth $407,000 after buying an additional 507 shares in the last quarter. Institutional investors own 97.79% of the company’s stock.

Analyst Upgrades and Downgrades

HALO has been the subject of a number of analyst reports. Cowen reiterated a “buy” rating on shares of Halozyme Therapeutics in a research report on Friday, October 18th. JMP Securities boosted their price target on Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a report on Friday, November 1st. JPMorgan Chase & Co. lowered Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and raised their price objective for the company from $52.00 to $57.00 in a research note on Thursday, September 19th. Piper Sandler lifted their target price on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a research report on Friday, January 10th. Finally, HC Wainwright increased their target price on shares of Halozyme Therapeutics from $68.00 to $70.00 and gave the stock a “buy” rating in a report on Friday, January 10th. Four research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $60.89.

Insider Activity

In other news, Director Jeffrey William Henderson sold 10,000 shares of the company’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $50.01, for a total transaction of $500,100.00. Following the transaction, the director now owns 43,611 shares of the company’s stock, valued at $2,180,986.11. This represents a 18.65 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Trading Up 2.7 %

NASDAQ HALO opened at $55.99 on Thursday. The stock has a market capitalization of $7.12 billion, a price-to-earnings ratio of 18.54, a PEG ratio of 0.40 and a beta of 1.24. The company has a debt-to-equity ratio of 3.32, a current ratio of 10.36 and a quick ratio of 9.15. Halozyme Therapeutics, Inc. has a one year low of $33.15 and a one year high of $65.53. The business’s fifty day moving average is $49.83 and its 200-day moving average is $54.06.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.